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Empirical evidence for discrete neurocognitive subgroups in 
bipolar disorder: clinical implications
K. E. Burdick1,*, M. Russo1, S. Frangou1, K. Mahon1, R. J. Braga2, M. Shanahan1, and A. K. 
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Abstract
Background—Recent data suggest trait-like neurocognitive impairments in bipolar disorder 
(BPD), with deficits about 1 s.D. below average, less severe than deficits noted in schizophrenia. 
The frequency of significant impairment in BPD is approximately 60%, with 40% of patients 
characterized as cognitively spared. This contrasts with a more homogeneous presentation in 
schizophrenia. It is not understood why some BPD patients develop deficits while others do not.
Method—A total of 136 patients with BPD completed the MATRICS Consensus Cognitive 
Battery and data were entered into hierarchical cluster analyses to: (1) determine the optimal 
number of clusters (subgroups) that fit the sample; and (2) assign subjects to a specific cluster 
based on individual profiles. We then compared subgroups on several clinical factors and real-
world community functioning.
Results—Three distinct neurocognitive subgroups were found: (1) an intact group with 
performance comparable with healthy controls on all domains but with superior social cognition; 
(2) a selective impairment group with moderate deficits on processing speed, attention, verbal 
learning and social cognition and normal functioning in other domains; and (3) a global 
impairment group with severe deficits across all cognitive domains comparable with deficits in 
schizophrenia.
Conclusions—These results suggest the presence of multiple cognitive subgroups in BPD with 
unique profiles and begin to address the relationships between these subgroups, several clinical 
factors and functional outcome. Next steps will include using these data to help guide future 
efforts to target these disabling symptoms with treatment.
Keywords
Bipolar disorder; cluster analysis; cognitive heterogeneity; functional outcome; neurocognition; 
schizophrenia
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Introduction
Neurocognitive impairment has long been recognized as a core feature of schizophrenia 
(Green, 1996) and is the focus of a multitude of studies. In contrast, the importance of 
cognitive problems in bipolar disorder (BPD) has only very recently been recognized, with 
the initial publications emerging in the late 1990s.
While there are considerable effects of mood state on cognition, with acutely manic or 
depressed patients demonstrating profound, global deficits (Daban et al. 2006), individuals 
with BPD also demonstrate persistent, trait-like, deficits during remission. Impairment is 
most notable in attention, verbal learning and executive function (Bora et al. 2009), with 
performance falling 0.5–1 s.D. below average. Moreover, as has been repeatedly shown in 
schizophrenia (Green, 1996; Ventura et al. 2009; Shamsi et al. 2011), these cognitive 
deficits contribute significantly to functional disability in BPD (Martinez-Aran et al. 2007; 
Bowie et al. 2010; Burdick et al. 2010; Harvey et al. 2010).
Although BPD has been characterized as an episodic illness with resultant functional 
recovery (Murray & Lopez, 1997), data emerging over the past several years have 
documented that neither complete symptomatic nor functional recovery is the norm (Tohen 
et al. 2003). Early data suggest that, as in schizophrenia (Dion et al. 1988; Abood et al. 
2002; Kupfer et al. 2002), BPD patients’ social, occupational and residential functioning is 
directly influenced by persistent symptomatology and cognitive dysfunction (Martinez-Aran 
et al. 2007; Bowie et al. 2010; Burdick et al. 2010; Depp et al. 2012). These data strongly 
support the importance of cognitive problems in relation to quality of life in BPD and 
highlight the need for treatment and prevention efforts targeting cognition (Burdick et al. 
2007). However, relatively little is known about the structure and causes of these deficits.
It is accepted that schizophrenia is characterized by some degree of cognitive heterogeneity, 
as demonstrated by the co-existence of a minority of cognitively unimpaired subgroup of 
subjects alongside the severe impairment characterizing the majority of schizophrenia 
subjects (Kremen et al. 2000; Reichenberg et al. 2009). Previous studies have reported 
variable performance on both specific cognitive tasks (Heinrichs & Awad, 1993; Goldstein 
et al. 1996) and global measures (Seaton et al. 1999; Hill et al. 2002). Generally, four 
subgroups have been described with two extreme subgroups, one with almost normal and 
one with profoundly impaired cognitive performance, and two intermediate subgroups, each 
with a moderate level of dysfunction across the cognitive domains (Goldstein et al. 1998; 
Seaton et al. 1999; Hill et al. 2002). While these studies showed that cognitive heterogeneity 
is present in schizophrenia, relatively little is known about heterogeneity of cognitive 
functioning in BPD subjects.
When analysed at the group level, studies have confirmed that neurocognitive deficits are 
present in euthymic BPD patients but that they are significantly less severe than those 
reported in schizophrenia (Daban et al. 2006; Burdick et al. 2011). These data suggest the 
existence of a gradation of severity in cognitive functioning between schizophrenia and BPD 
along a continuum of severity, which implies that group differences in cognitive 
performance are quantitative rather than qualitative. The same continuum of severity may be 
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present within each disorder; however, qualitatively distinct subgroups might also exist. 
Early data suggest that approximately 30–50% of BPD patients present as 
‘neuropsychologically normal’ (performing similar to healthy controls) during periods of 
euthymia (Heinrichs & Awad, 1993; Goldstein et al. 1996, 1998; Seaton et al. 1999; Hill et 
al. 2002; Martino et al. 2008; Bora et al. 2009; Reichenberg et al. 2009; Burdick et al. 
2011).
A study by Altshuler et al. (2004) highlights this issue where schizophrenia patients (n=20) 
were significantly impaired on nearly every cognitive task administered, while euthymic 
BPD patients (n=40) had significant deficits on only two tasks: the Wisconsin Card Sorting 
Task (WCST) and the California Verbal Learning Test. The BPD subjects, as a group, 
performed intermediate between the schizophrenia and healthy controls; however, BPD 
patients’ performance on the WCST showed a bimodal distribution, suggestive of two 
discrete subgroups – one with relatively normal and one with significantly impaired 
executive functioning (Altshuler et al. 2004). This is a critical issue in understanding the 
etiology of cognitive impairment in BPD, yet very little is currently known about why some 
patients with BPD develop significant cognitive deficits while others remain cognitively 
intact.
Several clinical factors (i.e. bipolar subtype, history of psychosis, number of prior episodes, 
age at onset and duration of illness) appear to increase the likelihood of significant cognitive 
impairment (Martinez-Aran et al. 2007; Bora et al. 2009). Some studies indicate that BPD I 
patients may be more impaired than BPD II patients (Simonsen et al. 2008), yet others argue 
that they are similarly impaired (Dittman et al. 2008; Rosa et al. 2010). This inconsistency 
may be due, in part, to psychosis in a subgroup of about 50% of BPD I patients v. much less 
frequent psychosis in BPD II (APA, 2000). Indeed, meta-analytic data suggest that BPD 
patients with psychosis perform worse than BPD patients who never experience psychosis, 
even during affective remission (Martinez-Aran et al. 2008; Bora et al. 2009). In addition 
the course of the illness varies considerably among BPD patients, particularly with regard to 
chronicity, and data suggest that more frequent severe episodes are associated with higher 
levels of cognitive dysfunction (Bora et al. 2009).
In the current study, we hypothesized that there would be evidence of discrete cognitive 
subgroups in BPD based on neurocognitive profiles. We were specifically interested in 
addressing this empirically to determine: (1) whether specific subgroups exist; (2) the 
optimal number of subgroups that explain the heterogeneity; (3) the qualitative 
neurocognitive profiles associated with these subgroups; and (4) the clinical and functional 
correlates associated with each subgroup.
Method
Participants
Patients—A total of 136 BPD out-patients were recruited at two sites: 113 from the Zucker 
Hillside Hospital (ZHH) – North Shore Long Island Jewish Health System; and 23 patients 
from the Icahn School of Medicine at Mount Sinai. Inclusion criteria were: (1) diagnosis of 
BPD I or BPD II; (2) age 18–65 years; (3) current affective stability [<12 on the Hamilton 
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Rating Scale for Depression (HAMD; Hamilton, 1960); and <8 on the Clinician-
Administered Rating Scale for Mania (CARS-M; Altman et al. 1994)]. Exclusion criteria 
were: (1) history of central nervous system (CNS) trauma, neurological disorder, or attention 
deficit hyperactivity disorder; (2) diagnosis of recent substance abuse/dependence (past 3 
months); and (3) electroconvulsive therapy (ECT) in the past 12 months.
A total of 105 patients were diagnosed with BPD I [n=60 (57.1%) with psychotic features] 
and 31 with BPD II [n=9 (29%) with psychotic features] based upon the Structured Clinical 
Interview for DSM-IV (SCID) and confirmed by a consensus panel. The mean age at the 
time of the assessment was 40.8 (S.D.=10.6) years, 50.0% (n=68) were female, and 49.3% 
(n=67) were Caucasian. The mean pre-morbid intelligence quotient (IQ) (Wide Range 
Achievement Test; WRAT-3; Wilkinson, 1993) was=97.6 (S.D.=10.8). The mean HAMD 
score (current depression) was 11.1 (S.D.=8.5) and the mean CARS-M (current mania) was 
5.5 (S.D.=7.0), indicative of affective stability.
A total of 148 healthy controls (HCs) with no evidence of Axis I disorders (SCID) were 
recruited through advertisements at ZHH. Mean age was 41.58 (S.D.=15.1) years, 43.9% 
(n=65) were female, 47.3% (n=70) were Caucasian, and the mean pre-morbid IQ was 
102.16 (S.D.=11.7). There were no significant differences between patients and controls 
(Table 1) in terms of age, sex or race (all p>0.05), while a difference was detected for pre-
morbid IQ (F1,267 = 10.71, p=0.001).
Measuring neurocognitive functioning
The MATRICS Consensus Cognitive Battery (MCCB; Nuechterlein et al. 2008; Matrics 
Assessment Inc., USA) was used to measure neurocognitive functioning. The MCCB was 
originally developed to be used in clinical trials targeting cognition in schizophrenia; 
however, recent studies demonstrated its suitability to effectively capture neurocognitive 
deficits in BPD patients (Yatham et al. 2010; Burdick et al. 2011). The MCCB is composed 
of several individual tests that give rise to seven cognitive domains:
1. Processing speed (Brief Assessment of Cognition in Schizophrenia and Trail 
Making Test-A);
2. Attention/vigilance (Continuous Performance Test–Identical Pairs);
3. Working memory (Wechsler Memory Scale: Spatial Span Letter-Number Span);
4. Verbal learning (Hopkins Verbal Learning Test–Revised);
5. Visual learning (Brief Visuospatial Memory Test–Revised);
6. Reasoning and problem solving (Neuropsychological Assessment Battery Mazes);
7. Social cognition (Mayer–Salovey–Caruso Emotional Intelligence Test).
The battery was completed in a single session of about 70 min.
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Measuring clinical features and functional disability
For a subsample of patients (sample sizes in tables) data on current symptoms, history of 
psychosis, number of mood episodes and lifetime history of co-morbid substance use 
disorders were collected using the SCID interview and standardized mood ratings.
A comprehensive functional outcome evaluation was done using the Multidimensional Scale 
of Independent Functioning (MSIF; Jaeger et al. 2003) and the Social Adjustment Scale-II 
(SAS-II; Schooler et al. 1979). The MSIF is able to separate out the contribution of role 
position, level of support, and adequacy of performance, providing anchors for rating 
functioning in work and residential domains. The SAS-II assesses social functioning through 
use of a semi-structured interview, resulting in a social/leisure rating. Higher scores on each 
of these scales correspond to worse community functioning.
Statistical analysis
Initial analyses were carried out to compare demographic and clinical characteristics, and 
cognitive performance of the BPD patients and HCs using analysis of variance (ANOVA) 
and χ2 as appropriate (Table 1). All cognitive data were standardized to a Z-scale score with 
a mean of 0 and S.D. of 1, based upon the HCs’ performance.
In order to identify homogeneous subgroups of BPD patients based on their cognitive 
performance, we conducted a hierarchical cluster analysis. Similarity between cases was 
computed with the squared Euclidian distance and the Ward linkage was selected as the 
agglomeration procedure. Since the variables (scores for each MCCB domain) had the same 
metrics (t-scores with a mean of 50 and S.D. of 10) no pre-standardization was necessary. 
The inspection of the dendogram was used as criterion to establish the appropriate number 
of clusters to retain. Therefore in a second step of the analysis the model was forced to 
include a meaningful number of clusters (deduced from the dendogram) and cluster 
membership was saved as a grouping variable. Stability of the clusters was ascertained by 
repeating the hierarchical cluster analysis in a split half of the sample. Then in order to test 
the validity of the clusters and to have a better understanding of the relationship between 
cognition and allocation of BPD patients into specific clusters, we conducted a discriminant 
function analysis (DFA). The DFA explored the predictive power of each of the seven 
MCCB domains in differentiating subjects into the discrete neurocognitive groups obtained 
from the hierarchical cluster analysis. The neurocognitive profiles of the BPD clusters and 
HCs were then compared using an ANOVA. Planned contrasts using the HC group as a 
comparison category was done to detect differences between groups and results were 
corrected for multiple comparisons with least significant difference (LSD) correction. We 
acknowledge that the clustering procedures were applied with the intent to separate the BPD 
sample into subgroups based on cognitive performance; therefore, it would follow that 
secondary testing for subgroup differences would be significant. The purpose of these 
analyses was not to prove that differences exist between the BPD subgroups. Rather, we 
carried out these analyses specifically in an effort to determine the degree of impairment 
versus HCs, to illustrate the qualitative differences among the BPD clusters, and to allow for 
a visualization of the profiles by subgroup.
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Finally, to begin to understand the clinical and functional correlates of cluster membership, 
descriptive analyses (ANOVA and χ2 applied as appropriate) were carried out to investigate 
differences on demographic characteristics, clinical features, and functional disability 
between the identified BPD clusters.
Results
Results from the ANOVA revealed that BPD patients (full sample) had significantly worse 
performance than HCs on all seven of the MCCB domains and on the MCCB composite 
score (all p<0.002; Table 1). These data are consistent with prior work from our group 
(Burdick et al. 2007) and others (Bora et al. 2009) and suggest that our BPD sample is 
representative of other samples in previous studies of neurocognition.
Clustering BPD patients
Results from the hierarchical cluster analysis showed that the 136 BPD patients are 
optimally clustered (according to MCCB performance) into three discrete subgroups. The 
first cluster included 54 subjects (39.7%), the second cluster included 43 individuals 
(31.6%) and the third cluster included 39 subjects (28.7%).
To test the validity of these clusters, approximately 50% of the 136 BPD patients (n=65) 
from the original sample were randomly selected and hierarchical cluster analysis was 
repeated on the split-half sample. Results were consistent with the initial analysis with the 
emergence of three clusters in the split sample. The ANOVA revealed no statistically 
significant differences between the two split samples in term of age, sex, diagnosis and 
neurocognitive performance.
Results from the DFA using the three BPD clusters revealed the presence of two 
discriminant functions explaining 65.6% and 34.4% of the variance, respectively (Wilks’ λ 
= 0.18, , p<0.001; after removal of the first function the Wilk’s λ = 0.51, 
, p<0.001). Visual learning and working memory domains showed the strongest 
correlation coefficients (0.78 and 0.51, respectively), suggesting that they contributed more 
than the other cognitive domains to classify subjects into neurocognitive clusters. Subjects 
grouping into the three neurocognitive clusters are shown in Fig. 1.
Comparison between BPD clusters and HCs on neurocognitive functioning
Multivariate ANOVA revealed a significant main effect of group when comparing the three 
BPD clusters and HCs (F21,828 =15.30, p <0.001) (Table 2). Based on the level of cognitive 
impairment, the BPD clusters were labeled as follows:
Cluster 1, the global impairment group (global), presented with diffuse and severe cognitive 
dysfunction, with performance falling between 1 and 2 s.D.s below the HCs’ mean;
Cluster 2, the selective impairment group (selective), presented with more modest deficits 
on specific domains, with performance ranging between normal and –1 s.D. below average;
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Cluster 3, the intact group (intact), performed comparably to HCs on all domains (all p 
values>0.07), with significantly superior performance v. HCs on social cognition (p=0.004) 
(Table 2).
Fig. 2 illustrates the cognitive profiles of the three BPD clusters and the schizophrenia 
sample. Z scores were computed based upon our HC sample instead of using the MCCB 
normative sample, as our HCs were demographically matched to our BPD sample on 
demographic characteristics (see Table 1) than the community sample used for 
standardization of the MCCB battery (Kern et al. 2008).
After LSD correction for multiple testing, the global group performed significantly worse 
than HCs across all cognitive domains. The selective group performed significantly worse 
than HCs on all domains except for visual learning and reasoning and problem solving. The 
intact group performed within the normal range for all domains v. HCs, apart from social 
cognition (p=0.004) where intact BPD subjects scored significantly higher than HCs (Table 
2).
For purposes of reference to the severity of cognitive impairment noted in schizophrenia, we 
have included in Fig. 2 data from a sample of 185 schizophrenia patients ascertained at ZHH 
using the same recruitment procedures as were used for the BPD sample selection. The 
mean age at the time of the assessment was 42.9 years (S.D.=1 0.1), mean age at onset was 
19.5 years (S.D.=8.7), and, on average, schizophrenia subjects had 12.7 years (S.D.=2.8) of 
education. Of the subjects, 57 (31.5%) were female and 77 (42.5%) were Caucasian. The 
mean pre-morbid IQ (WRAT-3) was=90.8 (S.D.=12.7) and the mean depressive symptoms 
score (as measured by the HAMD) was 10.4 (S.D.=7.0). Additional details regarding the 
schizophrenia sample have been previously described and published (Shamsi et al. 2011).
When comparing the global BPD group with the schizophrenia patients, the two groups did 
not differ on six of seven of the cognitive domains, nor did they differ on the MCCB 
composite score (all p<0.09). The only exception was for social cognition where the BPD 
global group outperformed the schizophrenia group [mean −0.70 (S.D.=1.30) v. −1.06 
(S.D.=1.16)].
Non-cognitive characteristics of the three BPD clusters (Table 3)
The three clusters did not differ on age, sex or race distributions; however, there were 
significant group differences for pre-morbid-IQ (F2,120 =8.46, p<0.001), with post-hoc tests 
indicating significant group differences between the global group and each of the other two 
clusters. There was no difference between the selective group and the intact group. As might 
be expected, subjects in the global group had the lowest pre-morbid IQ.
There were no significant differences for depressive or manic symptoms at the time of 
assessment. Diagnostic subtype distributions (BPD I v. BPD II) did not differ by cognitive 
group; nor did psychosis history (p=0.373 and p=0.159, respectively). There was no 
significant difference with regard to history of substance use disorder (inclusive of alcohol/
drug abuse/dependence; p=0.887).
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There was a main effect of group on total number of prior episodes (including both 
depressive and manic; p =0.042); post-hoc testing revealed significant differences between 
the intact and selective groups (p=0.014) and a trend-level difference between the global and 
intact groups (p =0.089). The selective group had the highest number of prior episodes but 
did not significantly differ from the global group (p=0.344). Likewise, while there was no 
main effect of group with regard to total number of previous depressive episodes (p=0.074), 
post-hoc results were significantly different between the intact and selective groups 
(p=0.025), with selective group subjects reporting the highest number of prior depressive 
episodes. There was no main effect of group on prior number of manic episodes (p=0.181) 
and no post-hoc group differences. There were no differences between the clusters on total 
number of medications or the types of medications prescribed.
When evaluating the influence of cluster membership on everyday functions, we found a 
significant main effect of group for MSIF occupational status (p=0.002), with significant 
post-hoc differences: global v. intact (p =0.001); selective v. intact (p=0.008). There were no 
significant effects on independent living status or social functioning.
Discussion
A convergence of anecdotal and clinically based evidence suggests that there is substantial 
heterogeneity in neurocognition and functional capacity in BPD patients. In this paper, we 
provide empirical support for statistically discrete neurocognitive subgroups in BPD, 
characterizing the structure of this heterogeneity.
Previous work has consistently shown that, as a group, remitted BPD patients are impaired 
about 0.5 to 1 s.D. below average, particularly on attention, verbal learning and executive 
functioning (Bora et al. 2009). While this level of impairment is considered modest, 
particularly in light of considerably more severe deficits in schizophrenia, these data fail to 
account for the substantial cognitive heterogeneity in BPD. Early data suggest that only a 
small proportion of patients with schizophrenia are considered ‘neuropsychologically 
normal’ (Wilk et al. 2005; Kremen et al. 2008), while nearly half of all BPD patients 
function within the average range (Martino et al. 2008; Bora et al. 2009; Reichenberg et al. 
2009). Thus, prior group-based analyses comparing these two samples may have failed to 
capture the extent of the impairment that is present in a specific subgroup of BPD patients. 
Indeed, our data strongly support this notion.
Using hierarchical cluster analyses, we found evidence for three distinct, cognitively 
homogeneous subgroups in an unselected sample of 136 BPD patients. Specifically we 
found: (1) a cluster of BPD patients with normal cognitive functioning (intact group; 31.6% 
of the sample) who do not differ from demographically matched HCs; (2) a cluster of BPD 
patients whose cognitive profile is consistent with selective impairment (selective group 
28.7% of the sample), with modest deficits on only a subset of the seven cognitive domains 
v. HCs; and (3) a cluster of BPD patients (global group; 39.7% of the sample) with severe 
impairment across all cognitive domains.
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The emergence of an intact group is consistent with prior reports that used a −1 s.D. cut-off 
to define clinically significant impairment and found that approximately 40% of BPD 
patients were characterized as unimpaired (Reichenberg et al. 2009). Our data expand upon 
this to show that there is a specific subgroup that not only fail to meet this threshold of 
impairment but indeed do not differ from HCs on any of the MCCB cognitive domains. 
Moreover, in line with the anecdotal evidence of a high-performing, socially savvy BPD 
subgroup, we found that the intact group was actually superior to our HCs on the MCCB 
social cognition domain. In addition, the global group performed better than the 
schizophrenia group on social cognition although their cognitive profiles were comparable 
across all the other domains. This result is consistent with a very recent study (Lee et al. 
2013) showing that social cognition in BPD is relatively intact. Lee et al. (2013) showed that 
BPD patients did not significantly differ from the comparison group on any social cognitive 
task and that BPD subjects performed significantly better on social compared with non-
social domains, while the opposite pattern emerged in schizophrenia patients. Although our 
findings support the presence of less severe impairment in social cognition compared with 
other domains in BPD patients when considered at a group level, it might also suggest the 
potential for meaningful subgroups based upon social cognitive performance within BPD. 
Future studies including a more extensive social cognitive battery will be needed to expand 
upon these results in order to determine whether social cognition can be considered a key 
determinant of poor functional outcome for those subgroups of BPD patients showing very 
severe cognitive deficits.
Subjects who were clustered into the selective group were characterized by a profile similar 
to that which is commonly noted in BPD group-level data. Deficits were noted on some but 
not all cognitive domains (intact visual learning and reasoning and problem solving) and 
were generally in the mild to moderate range.
The globally impaired group (global group) showed a generalized pattern of impairment 
with significant deficits on all cognitive domains when compared with HCs. Deficits in the 
global group were severe, ranging from −1 to −2 s.D.s below the mean performance of a HC 
sample, directly comparable with the impairment in our schizophrenia cohort (Shamsi et al. 
2011) (see Fig. 2) and in other samples of schizophrenia patients (Harvey & Serper, 1990; 
Heinrichs & Zakzanis, 1998). This overlapping profile is of critical importance when 
considering recent data supporting shared molecular genetic risk factors for BPD and 
schizophrenia (Lichtenstein et al. 2009; Williams et al. 2011). As illustrated in Fig. 2 the 
global measure of cognition (MCCB composite score) would suggest a continuum of 
severity across the full range of major psychiatric disease, such that all patients, regardless 
of diagnosis, could be characterized by mild, moderate or severe impairment. The overlap 
between the global BPD group and patients with schizophrenia argues that BPD patients do 
not simply lie intermediate between HCs and schizophrenia on this cognitive continuum. 
Moreover, when taking into account the performance on specific domains, the presence of 
qualitative differences across the three BPD clusters supports the existence of meaningfully 
unique subgroups within the illness.
The three BPD clusters did not differ with regard to age, sex or race distribution; however, 
pre-morbid IQ estimates were significantly different by group. The global group had the 
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lowest pre-morbid IQ and although it was still considered to be within the normal range, it 
was significantly lower than each of the other two BPD clusters and the HCs. The other two 
BPD clusters did not differ from one another, nor were they different from the HCs. This 
suggests that lower IQ prior to the onset of BPD might place a patient at increased risk for 
developing more severe and generalized neurocognitive deficits in the context of the illness. 
This is consistent with mild pre-morbid deficits seen in patients with schizophrenia 
(Woodberry et al. 2008) and could be conceptualized in reference to the cognitive reserve 
theory, where higher cognitive capacity could serve as protective against decline (Stern, 
2012). Longitudinal studies will be important to address this hypothesis.
Prior evidence suggests that diagnostic subtype within BPD may influence the extent of 
cognitive dysfunction; however, our data did not support this finding. The distribution of 
BPD I v. BPD II was comparable in all groups, as was the psychotic subtype of the illness. 
The lack of significant findings in our sample could be due to limited statistical power but it 
also speaks to the inconsistencies reported in previous studies (Dittmann et al. 2008; 
Simonsen et al. 2008) and the relative paucity of data on neurocognitive functioning across 
the entire BPD spectrum (Sole et al. 2012). As has been shown in several previous studies, 
the total number of affective episodes was related to neurocognitive impairment in our 
sample. We found that the selective group had the highest number of total episodes, 
including both depressive and manic polarities, with the global group falling intermediate to 
the selective and intact groups. These data further support the deleterious and potentially 
cumulative effects of full-blown affective episodes on neurocognitive functioning in BPD 
(Bora et al. 2009).
Although data were only available in a subset of the sample, thereby limiting our 
interpretation of these findings, our data also suggest that there are meaningful group 
differences with regard to everyday functioning in the community. Specifically we found 
that BPD patients in the global group were significantly more occupationally disabled than 
patients who were either in the selective or intact groups. These data are consistent with 
several prior reports that indicate that neurocognitive impairment is an important predictor 
of functional disability across many psychiatric disorders (Bowie et al. 2010) including BPD 
(Depp et al. 2012; Martinez-Aran et al. 2007; Burdick et al. 2010) and suggest that these 
clusters may have direct functional relevance.
As the MCCB was initially designed for assaying cognition in schizophrenia, the use of a 
more comprehensive, bipolar-specific, neurocognitive battery (e.g. Yatham et al. 2010) may 
have resulted in the emergence of different subgroups. Future studies including a larger 
number of tasks and measures of affective processing will be important in establishing and 
refining these profiles.
This is the first study describing the presence of empirically derived neurocognitive 
subgroups in BPD. The potential downstream implications of our findings are two-fold. By 
subgrouping BPD patients based on neurocognitive profiles we can reduce the heterogeneity 
of the phenotype to allow for a more targeted assessment of clinical and biological 
predictors of cognitive impairment in BPD. The identification of specific biomarkers and 
clinical factors that are associated with specific neurocognitive profiles will allow for the 
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tailoring of treatments to correct the cognitive dysfunction in BPD. Preventative and early 
intervention strategies might also be suggested based upon future studies utilizing this 
approach.
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Fig. 1. 
Graphical agglomeration of bipolar disorder (BPD) subjects using discriminant function 
analysis. The figure represents the agglomeration of subjects using the three clusters 
emerged from the hierarchical cluster analysis. The centroids (■) are the mean score for 
each cluster. Cluster 1 is the global impairment group, cluster 2 is the selective impairment 
group and cluster 3 is the intact group (see text).
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Fig. 2. 
Neurocognitive profiles of bipolar disorder clusters and the schizophrenia sample. The X-
axis indicates the MATRICS Consensus Cognitive Battery (MCCB) domains. The Y-axis 
depicts a Z-scale score with a mean of 0 and a standard deviation of 1. Z scores were 
computed based upon the healthy control sample. Patients are divided into lines based on 
scoring for each cognitive domain. Statistical comparisons among groups are specified in 
Table 2.
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